PCP2

Across TCGA pan-cancer cohorts, PCP2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PCP2 data layer compared with 29 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher PCP2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PCP2 expression acts as an unfavorable survival marker.

BLCA, THYM, and ESCA are the cancer types where PCP2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.051	0.720	<.001	48	view →
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
ESCA	OS	Median	II,III,IV	0.164	0.702	.001	33	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
COAD	DFS	Median	All	0.212	0.696	.009	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PCP2–BLCA (OS)

Open the BLCA breakdown →